Pharma Stocks Surge: Ajanta, Zydus, Emcure Eye Growth with Key Deals & Clean FDA Report

• Ajanta Pharma inked an in-licensing deal with Biocon Ltd. for Semaglutide, a GLP-1 receptor agonist, for exclusive marketing in 23 countries.
• Zydus Lifesciences partnered with Bioeq AG to license and commercialize NUFYMCO, an interchangeable biosimilar to Lucentis, in the US market.
• Emcure Pharma's Gujarat facility received a 'no action indicated' (NAI) EIR from the USFDA after a clean inspection, reflecting compliance.
• Semaglutide aims to improve glycemic control, with commercialization expected in late 2026 or early 2027 after regulatory approvals.
• NUFYMCO, a vascular endothelial growth factor inhibitor, is approved for treating neovascular age-related degeneration and diabetic macular edema.

Why It Matters: Major pharma players Ajanta, Zydus, and Emcure are poised for growth with strategic deals and regulatory wins.